Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 2-3/2018

01-09-2018

Thrombospondin-1 interactions regulate eicosanoid metabolism and signaling in cancer-related inflammation

Authors: Manuel U. Ramirez, Elizabeth R. Stirling, Nancy J. Emenaker, David D. Roberts, David R. Soto-Pantoja

Published in: Cancer and Metastasis Reviews | Issue 2-3/2018

Login to get access

Abstract

The metabolism of arachidonic acid and other polyunsaturated fatty acids produces eicosanoids, a family of biologically active lipids that are implicated in homeostasis and in several pathologies that involve inflammation. Inflammatory processes mediated by eicosanoids promote carcinogenesis by exerting direct effects on cancer cells and by affecting the tumor microenvironment. Therefore, understanding how eicosanoids mediate cancer progression may lead to better approaches and chemopreventive strategies for the treatment of cancer. The matricellular protein thrombospondin-1 is involved in processes that profoundly regulate inflammatory pathways that contribute to carcinogenesis and metastatic spread. This review focuses on interactions of thrombospondin-1 and eicosanoids in the microenvironment that promote carcinogenesis and how the microenvironment can be targeted for cancer prevention to increase curative responses of cancer patients.
Literature
1.
Bentley, A. A., & Adams, J. C. (2010). The evolution of thrombospondins and their ligand-binding activities. Molecular Biology and Evolution, 27, 2187–2197.CrossRefPubMedPubMedCentral
2.
Carlson, C. B., Lawler, J., & Mosher, D. F. (2008). Structures of thrombospondins. Cellular and Molecular Life Sciences, 65, 672–686.CrossRefPubMed
3.
Stenina-Adognravi, O. (2014). Invoking the power of thrombospondins: regulation of thrombospondins expression. Matrix Biology, 37, 69–82.CrossRefPubMed
4.
Halper, J., & Kjaer, M. (2014). Basic components of connective tissues and extracellular matrix: elastin, fibrillin, fibulins, fibrinogen, fibronectin, laminin, tenascins and thrombospondins. Advances in Experimental Medicine and Biology, 802, 31–47.CrossRefPubMed
5.
Huang, H., Campbell, S. C., Bedford, D. F., Nelius, T., Veliceasa, D., Shroff, E. H., Henkin, J., Schneider, A., Bouck, N., & Volpert, O. V. (2004). Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Molecular Cancer Research, 2, 541–550.PubMed
6.
Brennan, E. P., Nolan, K. A., Borgeson, E., Gough, O. S., McEvoy, C. M., Docherty, N. G., Higgins, D. F., Murphy, M., Sadlier, D. M., Ali-Shah, S. T., et al. (2013). Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFbetaR1. Journal of the American Society of Nephrology, 24, 627–637.CrossRefPubMedPubMedCentral
7.
Stenina-Adognravi, O. (2013) Thrombospondins: old players, new games. Current Opinion in Lipidology, 24, 401–409.
8.
9.
Rogers, N. M., Sharifi-Sanjani, M., Csanyi, G., Pagano, P. J., & Isenberg, J. S. (2014). Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and vascular responses in health and disease. Matrix Biology, 37, 92–101.CrossRefPubMed
10.
Soto-Pantoja, D. R., Kaur, S., & Roberts, D. D. (2015). CD47 signaling pathways controlling cellular differentiation and responses to stress. Critical Reviews in Biochemistry and Molecular Biology, 50, 212–230.CrossRefPubMedPubMedCentral
11.
Isenberg, J. S., Martin-Manso, G., Maxhimer, J. B., & Roberts, D. D. (2009). Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nature Reviews. Cancer, 9, 182–194.CrossRefPubMedPubMedCentral
12.
Martin-Manso, G., Galli, S., Ridnour, L. A., Tsokos, M., Wink, D. A., & Roberts, D. D. (2008). Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Research, 68, 7090–7099.CrossRefPubMedPubMedCentral
13.
Soto-Pantoja, D. R., Sipes, J. M., Martin-Manso, G., Westwood, B., Morris, N. L., Ghosh, A., Emenaker, N. J., & Roberts, D. D. (2016). Dietary fat overcomes the protective activity of thrombospondin-1 signaling in the Apc(Min/+) model of colon cancer. Oncogenesis, 5, e230.CrossRefPubMedPubMedCentral
14.
Serhan, C. N., & Savill, J. (2005). Resolution of inflammation: the beginning programs the end. Nature Immunology, 6, 1191–1197.CrossRefPubMed
15.
Nakanishi, M., & Rosenberg, D. W. (2013). Multifaceted roles of PGE2 in inflammation and cancer. Seminars in Immunopathology, 35, 123–137.CrossRefPubMed
16.
Kim, W., Lee, H. N., Jang, J. H., Kim, S. H., Lee, Y. H., Hahn, Y. I., Ngo, H. K., Choi, Y., Joe, Y., Chung, H. T., et al. (2017). 15-Deoxy-delta(12,14)-prostaglandin J2 exerts proresolving effects through nuclear factor E2-related factor 2-induced expression of CD36 and heme oxygenase-1. Antioxidants & Redox Signaling, 27, 1412–1431.CrossRef
17.
Roberts, W., Magwenzi, S., Aburima, A., & Naseem, K. M. (2010). Thrombospondin-1 induces platelet activation through CD36-dependent inhibition of the cAMP/protein kinase A signaling cascade. Blood, 116, 4297–4306.CrossRefPubMed
18.
Kuda, O., Jenkins, C. M., Skinner, J. R., Moon, S. H., Su, X., Gross, R. W., & Abumrad, N. A. (2011). CD36 protein is involved in store-operated calcium flux, phospholipase A2 activation, and production of prostaglandin E2. The Journal of Biological Chemistry, 286, 17785–17795.CrossRefPubMedPubMedCentral
19.
Kotla, S., Singh, N. K., Traylor Jr., J. G., Orr, A. W., & Rao, G. N. (2014). ROS-dependent Syk and Pyk2-mediated STAT1 activation is required for 15(S)-hydroxyeicosatetraenoic acid-induced CD36 expression and foam cell formation. Free Radical Biology & Medicine, 76, 147–162.CrossRef
20.
Jaffe, E. A., Ruggiero, J. T., & Falcone, D. J. (1985). Monocytes and macrophages synthesize and secrete thrombospondin. Blood, 65, 79–84.PubMed
21.
Daynes, R. A., & Jones, D. C. (2002). Emerging roles of PPARs in inflammation and immunity. Nature Reviews. Immunology, 2, 748–759.CrossRefPubMed
22.
23.
Funk, C. D. (2001). Prostaglandins and leukotrienes: advances in eicosanoid biology. Science, 294, 1871–1875.CrossRefPubMed
24.
Furuyashiki, T., & Narumiya, S. (2009). Roles of prostaglandin E receptors in stress responses. Current Opinion in Pharmacology, 9, 31–38.CrossRefPubMed
25.
Gao, A. G., Lindberg, F. P., Finn, M. B., Blystone, S. D., Brown, E. J., & Frazier, W. A. (1996). Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. The Journal of Biological Chemistry, 271, 21–24.CrossRefPubMed
26.
Asch, A. S., Tepler, J., Silbiger, S., & Nachman, R. L. (1991). Cellular attachment to thrombospondin. Cooperative interactions between receptor systems. The Journal of Biological Chemistry , 266, 1740–1745.PubMed
27.
Chung, J., Wang, X. Q., Lindberg, F. P., & Frazier, W. A. (1999). Thrombospondin-1 acts via IAP/CD47 to synergize with collagen in alpha2beta1-mediated platelet activation. Blood, 94, 642–648.PubMed
28.
Guo, N., Zabrenetzky, V. S., Chandrasekaran, L., Sipes, J. M., Lawler, J., Krutzsch, H. C., & Roberts, D. D. (1998). Differential roles of protein kinase C and pertussis toxin-sensitive G-binding proteins in modulation of melanoma cell proliferation and motility by thrombospondin 1. Cancer Research, 58, 3154–3162.PubMed
29.
Yao, M., Roberts, D. D., & Isenberg, J. S. (2011). Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP. Pharmacological Research, 63, 13–22.CrossRefPubMed
30.
Ding, X., Zhu, C., Qiang, H., Zhou, X., & Zhou, G. (2011). Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors. Biomedicine & Pharmacotherapy, 65, 486–490.CrossRef
31.
Arguello, M., Paz, S., Hernandez, E., Corriveau-Bourque, C., Fawaz, L. M., Hiscott, J., & Lin, R. (2006). Leukotriene A4 hydrolase expression in PEL cells is regulated at the transcriptional level and leads to increased leukotriene B4 production. Journal of Immunology, 176, 7051–7061.CrossRef
32.
Stein, E. V., Miller, T. W., Ivins-O’Keefe, K., Kaur, S., & Roberts, D. D. (2016). Secreted thrombospondin-1 regulates macrophage interleukin-1beta production and activation through CD47. Scientific Reports, 6, 19684.CrossRefPubMedPubMedCentral
33.
Stawski, L., Haines, P., Fine, A., Rudnicka, L., & Trojanowska, M. (2014). MMP-12 deficiency attenuates angiotensin II-induced vascular injury, M2 macrophage accumulation, and skin and heart fibrosis. PLoS One, 9, e109763.CrossRefPubMedPubMedCentral
34.
Martin-Manso, G., Navarathna, D. H., Galli, S., Soto-Pantoja, D. R., Kuznetsova, S. A., Tsokos, M., & Roberts, D. D. (2012). Endogenous thrombospondin-1 regulates leukocyte recruitment and activation and accelerates death from systemic candidiasis. PLoS One, 7, e48775.CrossRefPubMedPubMedCentral
35.
Doyen, V., Rubio, M., Braun, D., Nakajima, T., Abe, J., Saito, H., Delespesse, G., & Sarfati, M. (2003). Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. The Journal of Experimental Medicine, 198, 1277–1283.CrossRefPubMedPubMedCentral
36.
Sennlaub, F., Valamanesh, F., Vazquez-Tello, A., El-Asrar, A. M., Checchin, D., Brault, S., Gobeil, F., Beauchamp, M. H., Mwaikambo, B., Courtois, Y., et al. (2003). Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation, 108, 198–204.CrossRefPubMed
37.
Phelps, R. A., Broadbent, T. J., Stafforini, D. M., & Jones, D. A. (2009). New perspectives on APC control of cell fate and proliferation in colorectal cancer. Cell Cycle, 8, 2549–2556.CrossRefPubMed
38.
Hull, M. A., Faluyi, O. O., Ko, C. W., Holwell, S., Scott, D. J., Cuthbert, R. J., Poulsom, R., Goodlad, R., Bonifer, C., Markham, A. F., & Coletta, P. L. (2006). Regulation of stromal cell cyclooxygenase-2 in the ApcMin/+ mouse model of intestinal tumorigenesis. Carcinogenesis, 27, 382–391.CrossRefPubMed
39.
Chen, L. C., Hao, C. Y., Chiu, Y. S., Wong, P., Melnick, J. S., Brotman, M., Moretto, J., Mendes, F., Smith, A. P., Bennington, J. L., et al. (2004). Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Research, 64, 3694–3700.CrossRefPubMed
40.
Zhao, Y., Xiong, Z., Lechner, E. J., Klenotic, P. A., Hamburg, B. J., Hulver, M., Khare, A., Oriss, T., Mangalmurti, N., Chan, Y., et al. (2014). Thrombospondin-1 triggers macrophage IL-10 production and promotes resolution of experimental lung injury. Mucosal Immunology, 7, 440–448.CrossRefPubMed
41.
Hoxha, M. (2017). A systematic review on the role of eicosanoid pathways in rheumatoid arthritis. Advances in Medical Sciences, 63, 22–29.CrossRefPubMed
42.
Tahir, A., Bileck, A., Muqaku, B., Niederstaetter, L., Kreutz, D., Mayer, R. L., Wolrab, D., Meier, S. M., Slany, A., & Gerner, C. (2017). Combined proteome and eicosanoid profiling approach for revealing implications of human fibroblasts in chronic inflammation. Analytical Chemistry, 89, 1945–1954.CrossRefPubMed
43.
Chlopicki, S., Swies, J., Mogielnicki, A., Buczko, W., Bartus, M., Lomnicka, M., Adamus, J., & Gebicki, J. (2007). 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. British Journal of Pharmacology, 152, 230–239.CrossRefPubMedPubMedCentral
44.
Wozniacka, A., Wieczorkowska, M., Gebicki, J., & Sysa-Jedrzejowska, A. (2005). Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study. Clinical and Experimental Dermatology, 30, 632–635.CrossRefPubMed
45.
Rauch, I., Deets, K. A., Ji, D. X., von Moltke, J., Tenthorey, J. L., Lee, A. Y., Philip, N. H., Ayres, J. S., Brodsky, I. E., Gronert, K., & Vance, R. E. (2017). NAIP-NLRC4 inflammasomes coordinate intestinal epithelial cell expulsion with eicosanoid and IL-18 release via activation of caspase-1 and -8. Immunity, 46, 649–659.CrossRefPubMedPubMedCentral
46.
Wang, X., Shaw, D. K., Hammond, H. L., Sutterwala, F. S., Rayamajhi, M., Shirey, K. A., Perkins, D. J., Bonventre, J. V., Velayutham, T. S., Evans, S. M., et al. (2016). The prostaglandin E2-EP3 receptor axis regulates anaplasma phagocytophilum-mediated NLRC4 inflammasome activation. PLoS Pathogens, 12, e1005803.CrossRefPubMedPubMedCentral
47.
Sokolowska, M., Chen, L. Y., Liu, Y., Martinez-Anton, A., Qi, H. Y., Logun, C., Alsaaty, S., Park, Y. H., Kastner, D. L., Chae, J. J., & Shelhamer, J. H. (2015). Prostaglandin E2 inhibits NLRP3 inflammasome activation through EP4 receptor and intracellular cyclic AMP in human macrophages. Journal of Immunology, 194, 5472–5487.CrossRef
48.
Savill, J., Hogg, N., Ren, Y., & Haslett, C. (1992). Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. The Journal of Clinical Investigation, 90, 1513–1522.CrossRefPubMedPubMedCentral
49.
Chuang, P. C., Wu, M. H., Shoji, Y., & Tsai, S. J. (2009). Downregulation of CD36 results in reduced phagocytic ability of peritoneal macrophages of women with endometriosis. The Journal of Pathology, 219, 232–241.CrossRefPubMed
50.
Stern, M., Savill, J., & Haslett, C. (1996). Human monocyte-derived macrophage phagocytosis of senescent eosinophils undergoing Apoptosis Mediation by alpha v beta 3/CD36/thrombospondin recognition mechanism and lack of phlogistic response. The American Journal of Pathology, 149, 911–921.PubMedPubMedCentral
51.
Horie, S., Sugita, S., Futagami, Y., Yamada, Y., & Mochizuki, M. (2010). Human retinal pigment epithelium-induced CD4+CD25+ regulatory T cells suppress activation of intraocular effector T cells. Clinical Immunology, 136, 83–95.CrossRefPubMed
52.
53.
Bielenberg, D. R., & Zetter, B. R. (2015). The contribution of angiogenesis to the process of metastasis. Cancer Journal, 21, 267–273.CrossRef
54.
Lawler, P. R., & Lawler, J. (2012). Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harbor Perspectives in Medicine, 2, a006627.CrossRefPubMedPubMedCentral
55.
Isenberg, J. S., Frazier, W. A., & Roberts, D. D. (2008). Thrombospondin-1: a physiological regulator of nitric oxide signaling. Cellular and Molecular Life Sciences, 65, 728–742.CrossRefPubMed
56.
Isenberg, J. S., Annis, D. S., Pendrak, M. L., Ptaszynska, M., Frazier, W. A., Mosher, D. F., & Roberts, D. D. (2009). Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. The Journal of Biological Chemistry, 284, 1116–1125.CrossRefPubMedPubMedCentral
57.
Isenberg, J. S., Jia, Y., Fukuyama, J., Switzer, C. H., Wink, D. A., & Roberts, D. D. (2007). Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. The Journal of Biological Chemistry, 282, 15404–15415.CrossRefPubMedPubMedCentral
58.
Isenberg, J. S., Ridnour, L. A., Dimitry, J., Frazier, W. A., Wink, D. A., & Roberts, D. D. (2006). CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. The Journal of Biological Chemistry, 281, 26069–26080.CrossRefPubMed
59.
60.
Nakanishi, M., Sato, T., Li, Y., Nelson, A. J., Farid, M., Michalski, J., Kanaji, N., Wang, X., Basma, H., Patil, A., et al. (2012). Prostaglandin E2 stimulates the production of vascular endothelial growth factor through the E-prostanoid-2 receptor in cultured human lung fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 46, 217–223.CrossRefPubMedPubMedCentral
61.
Greene, E. R., Huang, S., Serhan, C. N., & Panigrahy, D. (2011). Regulation of inflammation in cancer by eicosanoids. Prostaglandins & Other Lipid Mediators, 96, 27–36.CrossRef
62.
Jais, A., Einwallner, E., Sharif, O., Gossens, K., Lu, T. T., Soyal, S. M., Medgyesi, D., Neureiter, D., Paier-Pourani, J., Dalgaard, K., et al. (2014). Heme oxygenase-1 drives metaflammation and insulin resistance in mouse and man. Cell, 158, 25–40.CrossRefPubMedPubMedCentral
63.
Valderrama, J. A., Durante-Rodriguez, G., Blazquez, B., Garcia, J. L., Carmona, M., & Diaz, E. (2012). Bacterial degradation of benzoate: cross-regulation between aerobic and anaerobic pathways. The Journal of Biological Chemistry, 287, 10494–10508.CrossRefPubMedPubMedCentral
64.
Lees, H. J., Swann, J. R., Wilson, I. D., Nicholson, J. K., & Holmes, E. (2013). Hippurate: the natural history of a mammalian-microbial cometabolite. Journal of Proteome Research, 12, 1527–1546.CrossRefPubMed
65.
Dannenberg, A. J., Altorki, N. K., Boyle, J. O., Dang, C., Howe, L. R., Weksler, B. B., & Subbaramaiah, K. (2001). Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. The Lancet Oncology, 2, 544–551.CrossRefPubMed
66.
Haviv, F., Bradley, M. F., Kalvin, D. M., Schneider, A. J., Davidson, D. J., Majest, S. M., McKay, L. M., Haskell, C. J., Bell, R. L., Nguyen, B., et al. (2005). Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. Journal of Medicinal Chemistry, 48, 2838–2846.CrossRefPubMed
67.
Punekar, S., Zak, S., Kalter, V. G., Dobransky, L., Punekar, I., Lawler, J. W., & Gutierrez, L. S. (2008). Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology, 75, 9–21.CrossRefPubMed
68.
Baker, L. H., Rowinsky, E. K., Mendelson, D., Humerickhouse, R. A., Knight, R. A., Qian, J., Carr, R. A., Gordon, G. B., & Demetri, G. D. (2008). Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. Journal of Clinical Oncology, 26, 5583–5588.CrossRefPubMed
69.
Gutierrez, L. S., Ling, J., Nye, D., Papathomas, K., & Dickinson, C. (2015). Thrombospondin peptide ABT-898 inhibits inflammation and angiogenesis in a colitis model. World Journal of Gastroenterology, 21, 6157–6166.CrossRefPubMedPubMedCentral
70.
Metadata
Title
Thrombospondin-1 interactions regulate eicosanoid metabolism and signaling in cancer-related inflammation
Authors
Manuel U. Ramirez
Elizabeth R. Stirling
Nancy J. Emenaker
David D. Roberts
David R. Soto-Pantoja
Publication date
01-09-2018
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2-3/2018
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-018-9737-x

Other articles of this Issue 2-3/2018

Cancer and Metastasis Reviews 2-3/2018 Go to the issue

OriginalPaper

mPGES-1 and ALOX5/-15 in tumor-associated macrophages

OriginalPaper

Targeting the enzymes involved in arachidonic acid metabolism to improve radiotherapy

OriginalPaper

Lack of effective translational regulation of PLD expression and exosome biogenesis in triple-negative breast cancer cells

OriginalPaper

Eicosanoid signaling in carcinogenesis of colorectal cancer

OriginalPaper

The roles of the COX2/PGE2/EP axis in therapeutic resistance

Announcement

Biographies

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits